NCT06470139

Brief Summary

Effect of adding Dexamethasone to Periarticular Nerve Group Block in Patients undergoing Total Hip Arthroplasty

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Aug 2024

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 17, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 24, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

August 13, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2025

Completed
26 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 10, 2025

Completed
Last Updated

March 24, 2025

Status Verified

March 1, 2025

Enrollment Period

5 months

First QC Date

June 17, 2024

Last Update Submit

March 20, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time to first rescue opioid analgesia

    Time after surgery when the patient needs opiate for the first time

    48 hours after surgery

Secondary Outcomes (17)

  • Total Opioid Consumption

    48 hours after surgery

  • Numerical Rating Scale [range 0:10]

    4 hours after surgery

  • Numerical Rating Scale [range 0:10]

    8 hours after surgery

  • Numerical Rating Scale [range 0:10]

    12 hours after surgery

  • Numerical Rating Scale [range 0:10]

    24 hours after surgery

  • +12 more secondary outcomes

Study Arms (2)

Ropivacaine

ACTIVE COMPARATOR

Ultrasound-guided PENG block - 20ml 0,2% ropivacaine + 2ml 0.9% NaCl

Drug: Ropivacaine 0.2% Injectable Solution

Ropivacaine+Dexamethasone

ACTIVE COMPARATOR

Ultrasound-guided PENG block - 20ml 0,2% ropivacaine + 4mg Dexamethasone

Drug: Ropivacaine 0.2% Injectable Solution + 4mg Dexamethasone

Interventions

20ml 0.2% Ropivacaine + 2.0ml 0.9% NaCl

Ropivacaine

20ml 0.2% Ropivacaine + 4mg Dexamethasone

Ropivacaine+Dexamethasone

Eligibility Criteria

Age65 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • patients scheduled for total hip arthroplasty
  • patients aged \>65 and \<100 years
  • patients able to provide informed consent
  • patients able to reliably report symptoms to the research team

You may not qualify if:

  • inability to provide first-party consent due to cognitive impairment or a language barrier

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Poznan University of Medical Sciences

Poznan, Poznań, 61-701, Poland

Location

MeSH Terms

Conditions

Osteoarthritis, Hip

Interventions

RopivacaineDexamethasone

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesPregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Study Officials

  • Malgorzata Domagalska, M.D. Ph.D.

    Poznań University of Medical Sciences

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 17, 2024

First Posted

June 24, 2024

Study Start

August 13, 2024

Primary Completion

January 15, 2025

Study Completion

February 10, 2025

Last Updated

March 24, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will share

Locations